It was a busy week for the Contemporary OB/GYN team.
Here's what you missed:
Barb Dehn, NP, discusses vaccine hesitancy, soy and estrogen receptors, and a hospital in Tanzania dedicated to improving women's health through quality health care and education in under-resourced communities.
The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.
According to guidelines, there is only 1 temporary cure for this condition and that is antibiotics. As more antibiotics are taken by this susceptible population, however, the bacteria can adapt and make recurrent UTI treatment in the future much more difficult.